modelCicloniumAndAnalgesics
Extends from Pharmacolibrary.Drugs.ATC.A.A03DA04.
Information
| name: | CicloniumAndAnalgesics | |
| ATC code: | A03DA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 6 | L/h |
| other parameters in model implementation | ||
Ciclonium is an antispasmodic drug belonging to the class of quaternary ammonium compounds, used in combination with analgesics for the treatment of gastrointestinal spasms and related pain. It acts by inhibiting muscarinic receptors leading to smooth muscle relaxation. This ATC code refers to fixed-dose combinations of ciclonium with analgesic agents. Ciclonium is an older drug, not widely used or approved in many countries today.
Pharmacokinetics
No published human pharmacokinetic studies found; values below are model estimates based on the profile of similar quaternary ammonium antispasmodics administered orally in adults.
References
Lugo, RA, & Kern, SE (2004). The pharmacokinetics of oxycodone. Journal of pain & palliative care pharmacotherapy 18(4) 17–30. DOI:10.1300/j354v18n04_03 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15760805
Moore, RA, et al., & Straube, S (2015). Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. British journal of clinical pharmacology 80(3) 381–388. DOI:10.1111/bcp.12628 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25784216
Thigpen, JC, et al., & Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. European journal of drug metabolism and pharmacokinetics 44(5) 591–609. DOI:10.1007/s13318-019-00552-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31006834
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)